While we’re all very aware of the challenges tied to the reauthorization process, I also want to keep an eye on topics that matter for the long term— especially for those putting together SBIR proposals in the future.
February 24, 2026
Todd Strother, PhD
January 5, 2026
Unlock Translational Momentum with the Catalyze Grant
The NIH Catalyze program empowers innovators to fast-track heart, lung, blood, and sleep (HLBS) discoveries toward real-world impact.
January 2, 2026
Successful Business Transitioning Characteristics
I was recently asked “What distinguishes SBIR/STTR companies that successfully transition into investor-ready ventures? Are there certain characteristics?” Here are a couple of points that struck me right away.
January 2, 2026
Is your innovation right for Army FUZE?
The Defense TechConnect Innovation Summit, in conjunction with the SBIR/STTR Fall Innovation Conference was recently held in National Harbor.
November 24, 2025
Reauthorization updates from TechConnect 2025
The SBIR/STTR Fall Innovation Conference was held recently in conjunction with the Defense TechConnect Summit.
August 29, 2025
NIH Applications rejected for failing Foreign Risk Assessment
Recently we have had numerous NIH SBIR/STTR proposals rejected because they have failed the foreign risk assessment.
August 25, 2025
Safeguarding Originality: NIH’s New Limits on AI Use and Application Volume
Note: Ironically written by ChatGPT and edited by real humans.
August 11, 2025
Prompting TurboInnovate with CTC
You may recall that the CTC has a license to the Omnisync TurboInnovate platform.
March 11, 2025
Access Market Analysis from CTC
We, at the CTC, are excited to announce a new free service we are offering to our clients! We are now able to provide initial Market Research and Competitive Landscape Reports for our client’s technologies and companies.
February 10, 2025
Notice of NIH indirect rate decrease to 15%
Historically the NIH has allowed a 40% indirect rate on SBIR and STTR grants without requiring backing evidence.